Clinical Trial Update: Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

View source ↗

Summary

An observational trial to characterize biomarkers and disease progression in MECP2 duplication syndrome sponsored by Ionis Pharmaceuticals has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mecp2 Duplication Syndrome

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Status: TERMINATED